<DOC>
	<DOC>NCT00904059</DOC>
	<brief_summary>The purpose of this study is to assess the pharmacokinetics and safety of BMS-790052 and BMS-650032 when co-administered and when administered alone</brief_summary>
	<brief_title>Drug-Drug Interaction Study in Healthy Subjects</brief_title>
	<detailed_description>Pharmacokinetics and Safety in Healthy Subjects</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Healthy male and female subjects aged 18 to 49 years Females who are not of childbearing potential, pregnant or breastfeeding Subject Body Mass Index (BMI) of 18 to 32 kg/mÂ² Women of child bearing potential Male subjects who have sex with women who are unwilling to agree to practice male barrier contraception during study participation and for a least 12 weeks following dosing Any significant acute or chronic medical illness Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations Prior exposure to BMS650032 or BMS790052 Positive for HIV or HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>